AbbVie vs. Novo Nordisk: Which Drug Giant Stock Is a Better Buy in 2026?

Novo Nordisk is presented as the more attractive 2026 valuation choice, trading at 12.1x forward P/E and 3.5x sales versus AbbVie's 16.4x and 7.3x, respectively. Novo generated about $47B of FY2025 revenue and $16B of net income (33% margin), but Wall Street expects FY2026 sales to decline 3% and net income to fall 4% amid GLP-1 pricing pressure and competition. AbbVie delivered roughly $61.2B of FY2025 revenue, up 9%, and is projected to increase sales to $67.2B and net income from about $4.2B to $14.6B, supported by Skyrizi, Rinvoq, pipeline prospects, and its Apogee Therapeutics acquisition.

Analysis

The relevant relative-value setup is not “diversified pharma versus GLP-1 growth,” but earnings-revision asymmetry. ABBV’s immunology franchise needs to demonstrate durable post-Humira replacement growth while its operating leverage normalizes after acquisition-related costs; that creates a plausible 1-3 month upside revision cycle if Skyrizi/Rinvoq uptake and pipeline milestones hold. NVO, conversely, is priced on the durability of an obesity profit pool that is becoming more contested: incremental supply from NVO and LLY can improve volumes but also shift bargaining power toward PBMs and payers, limiting the margin benefit of demand growth.

The market may be underweight ABBV’s cash-flow optionality and overstate the signal in negative book equity. For a mature pharmaceutical company, debt service coverage, debt maturities, and FCF after dividends matter more than debt-to-equity; sustained high-teens-billion-dollar FCF would support deleveraging, buybacks, and business-development capacity. The key ABBV risk is that IRA exposure, biosimilar erosion, and an acquisition-led pipeline leave it dependent on a narrow set of growth assets; failure to reaffirm immunology guidance or a negative Parkinson’s regulatory outcome would remove the re-rating case quickly.

For NVO, a lower headline earnings multiple is not automatically cheap if estimates still embed an optimistic price/volume mix. The central 6-18 month issue is whether oral GLP-1 expands the treated population without materially cannibalizing injectable economics, while LLY’s efficacy and manufacturing trajectory determine category share. The article’s references to generic competition and federal pricing arrangements require independent verification before trading: the timing, product scope, and net-price effect—not list-price headlines—will determine whether NVO faces a temporary 2026 trough or a structural margin reset.

Distributors MCK, COR, and CAH are secondary beneficiaries of greater GLP-1 prescription volumes, but their economics are principally tied to working-capital turns and service fees rather than drug price. They offer a cleaner way to express sustained specialty-drug volume growth if branded-manufacturer price risk rises, although reimbursement reform or adverse inventory timing can compress their returns.

Key Decisions for Investors

• Initiate a 3-6 month relative-value position: long ABBV / short NVO, sized beta-neutral, only after validating consensus 2026-27 EPS and FX assumptions. Thesis is ABBV estimate upgrades versus NVO net-price/mix downgrades; target 10-15% relative outperformance. Exit if ABBV immunology guidance is cut or NVO demonstrates stable net pricing with accelerating prescription share for two consecutive monthly data periods.
• Treat NVO as a watchlist long rather than a fresh directional purchase until U.S. formulary positioning, realized GLP-1 net price, and oral-product cannibalization are disclosed. A 2026 earnings trough with maintained 2027 volume guidance would be a potential entry signal; an adverse reimbursement decision or margin-guide cut would imply a structurally lower multiple.
• For long-only healthcare exposure, favor ABBV over NVO through the next FDA/pipeline catalyst window, with a risk limit tied to a break in Skyrizi/Rinvoq combined growth guidance. The payoff is multiple expansion from reduced post-Humira uncertainty; the principal downside is that M&A and pipeline spending prevent FCF from converting into deleveraging.
• Use MCK or COR as a lower-drug-pricing-beta satellite long only if specialty prescription growth remains strong; avoid CAH as the default proxy without confirming its segment-level profitability and working-capital trend. This is a 6-18 month volume/complexity trade, not a direct GLP-1 price-upside trade.